Saga Diagnostics Gains Medicare Coverage for Breast Cancer Recurrence Test

Saga Diagnostics’ Pathlight molecular residual disease (MRD) test has received positive Medicare coverage through the MolDx program for surveillance monitoring of breast cancer recurrence across all subtypes in stage II-III patients. The blood-based digital PCR assay detects patient-specific tumor DNA alterations with high sensitivity and a lead time of over a year compared to standard methods. This coverage opens broader access to ultrasensitive recurrence monitoring, potentially enabling earlier intervention and personalized patient management.